BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA

被引：0
|
作者：
Djambazov, S. [1 ]
Slavchev, G. [1 ]
Velchev, M. [2 ]
Vekov, T. [3 ]
机构：
[1] HTA Ltd, Sofia, Bulgaria
[2] Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria
[3] Med Univ Pleven, Pleven, Bulgaria
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN57
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [21] Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
    Dieras, Veronique
    Rugo, Hope S.
    Schnell, Patrick
    Gelmon, Karen
    Cristofanilli, Massimo
    Loi, Sherene
    Colleoni, Marco
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric
    Huang Bartlett, Cynthia
    Slamon, Dennis J.
    Turner, Nicholas C.
    Finn, Richard S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (04): : 419 - 430
  • [22] CLINICAL AND ECONOMIC ANALYSIS OF EFFECTIVENESS OF EVEROLIMUS IN THE TREATMENT OF HR+, HER2-ADVANCED BREAST CANCER IN RUSSIA
    Krasnova, L.
    Vorobiev, P.
    Holownia, M.
    VALUE IN HEALTH, 2014, 17 (07) : A635 - A635
  • [23] BUDGET IMPACT ANALYSIS OF FIRST-LINE RIBOCICLIB IN THE TREATMENT OF PRE- AND POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN THE UNITED STATES
    Zhou, J.
    Edwards, M. L.
    Fang, H.
    Oderda, G.
    Brixner, D.
    Biskupiak, J. E.
    Balu, S.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [24] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [25] Abemaciclib for treating patients with HR+, HER2-advanced/metastatic breast cancer in Spain: a real-world study
    Blancas, I.
    Fakhouri, W.
    Molero, A.
    Diaz-Cerezo, S.
    Haro, J. M.
    Faris, L. H.
    Sanchez-Bayona, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S59 - S60
  • [26] Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Barriga, Susana
    Lin, Yong
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
  • [28] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
    Dalal, Anand A.
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (09) : 1356 - 1367
  • [29] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
12345